HTG Molecular Diagnostics, Inc. Common Stock
HTGM
HTGM was delisted on the 14th of June, 2023.
22 hedge funds and large institutions have $7.65M invested in HTG Molecular Diagnostics, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 2 closing their positions.
4% less funds holding
Funds holding: 23 → 22 (-1)
16% less capital invested
Capital invested by funds: $9.07M → $7.65M (-$1.41M)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
56% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$39.3K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$26.4K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$7.15K |
| 4 |
TWA
TCI Wealth Advisors
Tucson,
Arizona
|
+$894 |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$447 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
-$80K |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$56.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$51K |
| 4 |
BG
BlackRock Group
London,
United Kingdom
|
-$21K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$9.39K |
HTGM Hedge Fund Activity: Q3 2016 in Review
22 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q3 2016, worth a combined $7.65M — down 16% from $9.07M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of HTGM and 1 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $39.3K. The largest seller was Mackenzie Financial, exiting entirely with an estimated $80K sold.
- 22 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q3 2016, down from 23 in Q2 2016.
- Funds reported $7.65M of HTG Molecular Diagnostics, Inc. Common Stock stock for Q3 2016, down 16% quarter-over-quarter.
- 1 fund opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q3 2016 and 2 closed out, a net change of -1 holder.
- The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q3 2016 was Renaissance Technologies, an estimated $39.3K added.
- The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q3 2016 was Mackenzie Financial, an estimated $80K sold.
Based on aggregated 13F filings for Q3 2016.